Incyte Corp.
Incyte Corp. (INCY): 94 pipeline candidates · 30 upcoming catalysts · ~15 mo cash runway · 168 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
14.5 months
D/E 0.31 · 3% dilution
Lead: Phase 3
94 candidates
30 upcoming, next in ~71d
0 buys · 8 sells (180d)
A transparent, data-derived signal for Incyte Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$20.1B
Cash
$3.5B
Quarterly Burn
$844.0M
Runway
14.5 mo
Revenue
$1.3B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (94 candidates)
| Drug | Phase |
|---|---|
| abiraterone | Phase 1/Phase 2 |
| adagrasib | Phase 1 |
| all-trans retinoic acid | Phase 1/Phase 2 |
| asparaginase erwinia chrysanthemi | Phase 2 |
| axatilimab | Phase 3 |
| axitinib | Phase 4 |
| bendamustine | Phase 2/Phase 3 |
| best available therapy | Phase 3 |
| best available treatment | Phase 3 |
| calcineurin inhibitor | Phase 1 |
Showing 10 of 94 candidates. Sign up for full pipeline.
Upcoming Catalysts (30)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
810
Total value held
$18.98B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 30,744,412 | $2.89B |
| vanguard capital management llc | 21,860,132 | $2.06B |
| blackrock, inc. | 18,978,198 | $1.79B |
| dodge & cox | 12,252,356 | $1.15B |
| state street corp | 9,641,384 | $907.4M |
| vanguard portfolio management llc | 7,759,183 | $730.3M |
| aqr capital management llc | 5,807,930 | $536.1M |
| geode capital management, llc | 4,703,184 | $441.1M |
| renaissance technologies llc | 3,651,532 | $343.7M |
| wellington management group llp | 3,266,136 | $307.4M |
Showing top 10 of 810 institutional holders of Incyte Corp.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Incyte Corp.'s pipeline?
Incyte Corp. (INCY) has 94 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Incyte Corp.'s lead drug candidate?
Incyte Corp.'s most advanced tracked candidate is abiraterone (Phase 1/Phase 2) for Solid Tumors.
What is Incyte Corp.'s next catalyst?
Incyte Corp.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012" — expected August 28, 2026.
What is Incyte Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Incyte Corp. has approximately 14.5 months of cash runway.
What is Incyte Corp.'s market capitalization?
Incyte Corp.'s market capitalization is approximately $20.1B.
Get the full picture on Incyte Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.